Trial Profile
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 18 Oct 2021
Price :
$35
*
At a glance
- Drugs Tanezumab (Primary) ; Tanezumab (Primary)
- Indications Musculoskeletal pain; Osteoarthritis
- Focus Adverse reactions; Registrational; Therapeutic Use
- 09 Oct 2021 Results of a subgroup analysis of pooled data from phase III placebo-controlled trials (NCT02697773, NCT02709486, and NCT01089725 (only safety) assessing the impact of pre-specified patient characteristics on efficacy and safety of subcutaneous tanezumab in patients with osteoarthritis published in the International Journal of Clinical Practice
- 22 Apr 2021 Results of a pooled analysis (NCT01089725, NCT02697773, NCT02709486 and NCT02528188) assessing the peripheral nerve safety of subcutaneous tanezumab versus placebo or nonsteroidal anti-inflammatory drugs presented at the 73rd Annual Meeting of the American Academy of Neurology
- 03 Nov 2020 Results of a pooled analysis of data pooled from 6 trials assessing the relative efficacy and tolerability of 2.5, 5, and 10 mg tanezumab for the treatment of osteoarthritis published in the International Journal of Clinical Pharmacology and Therapeutics